Abingworth oversubscribed at $465m for new life sciences fund Abingworth Bioventures 8

Asante Capital are thrilled to announce the final closing of Abingworth Bioventures 8 (ABV 8) which took place at $465 million, exceeding its target and closing at the hard cap.

Abingworth is a leading international life sciences investment group targeting companies developing innovative therapeutics with potential to significantly improve human health. Abingworth will invest in opportunities in the US, UK and Continental Europe and broadly across multiple stages including seed and early stage, development-stage companies, including VIPEs (Venture Investments in Public Equities), and Clinical Co-development opportunities.  

Asante Capital Group acted as global placement advisor for the fundraise.

To read more, please see below:


Artá Capital races to first close with commitments of €305m on a target of €400m

We are pleased to announce that Artá Capital Partners (“Artá”), a leading Iberian private equity firm, has raised over three quarters of their €400m target at the first close of Artá Capital Fund III LP (“Fund III”).

Winner at Private Equity Wire Awards 2023

We are honoured to be named Best Placement Agent as part of Private Equity Wire’s European Awards 2023! Winners were selected based on performance data and industry voting.

Asante Capital Solutions – Q4 2022 Newsletter

Following a decade of robust and unprecedented growth in the Asia-Pacific private equity region, 2022 brought with it a combination of challenges, ranging from the lingering effects of the COVID pandemic, global economic downturn and general macro uncertainty, casting a dark cloud over the region’s private markets. The answer to what the market in 2023 will look like is multi-faceted: in this newsletter, we are putting a spotlight on the key trends we are seeing in the APAC region and assessing their impact on the fundraising landscape.